TOKYO & PENNINGTON, N.J.--(BUSINESS WIRE)--Kyorin Pharmaceuticals Co., Ltd (Kyorin) and BioLeap, Inc. (BioLeap) have entered into a research collaboration that will use molecular design technology developed at BioLeap to produce novel drug candidates. Under the agreement, BioLeap will use their proprietary technology in computational fragment-based design to identify compounds aimed at biological targets of interest to Kyorin. A team of technical experts from both Kyorin and BioLeap will then select compounds for synthesis and in vitro and in vivo evaluation by Kyorin. Terms of the agreement including discovery milestones were not disclosed.
